Nine more months of life: a cervical cancer treatment proves its benefit lasts

For women whose cervical cancer has spread or come back, time is the thing treatment is really buying. At the ESMO congress, Ana Oaknin presented the final results of the BEATcc trial: adding the immunotherapy drug atezolizumab to standard chemotherapy and bevacizumab helped women live a median of 31.9 months, against 22.7 months without it — and four years on, 40% of women on the combination were still alive, compared with 26% on standard treatment. The benefit held across patient groups, and no new safety concerns appeared in nearly five years of follow-up.

SDG 3 · Good health and well-being — Mechanism: tech innovation